Project Grant R21AI194044
Award Date
7/25/25
Completion Date
6/30/27
Dollars Obligated
$424K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
This Project Grant award of $427,625.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Washington University to discover novel anti-biofilm agents derived from bacteriophages. The goal is to develop alternative therapies for treating biofilm-associated infections, which are a major challenge for pathogens like Pseudomonas aeruginosa. The research will isolate phages that can overcome biofilm barriers,...
The Stanford University received a $337,147 Project Grant award from the National Institute of Allergy and Infectious Diseases to develop an immunization against Pseudomonas aeruginosa infection. The grant supports research to evaluate the effectiveness of antibodies against bacteriophage PF in promoting phagocytosis and clearance of P. aeruginosa, determining the ability of anti-PF antibodies to protect against multiple clinical strains, and examining the presence of anti-PF antibodies in human...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $794,849 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Cedars-Sinai Medical Center. The grant will fund research to investigate mechanisms of cefiderocol resistance and cross-protection in Pseudomonas aeruginosa, a common lung infection in cystic fibrosis patients. Key objectives include determining how mutations in the CpxS two-component sensor system impact siderophore...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,388,838 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Research Foundation For The State University Of New York (RF SUNY) to optimize phage cocktail regimens for treating extensively drug-resistant Pseudomonas aeruginosa. The project aims to: 1) develop a quantification assay for the phage cocktail, 2) identify optimal phage combinations and administration patterns...
This Project Grant award of $868,776.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to characterize a novel post-transcriptional regulator in the opportunistic pathogen Pseudomonas aeruginosa. The key objectives are to: Identify the direct regulatory targets of the RNA-binding protein PhaF under standard lab conditions, infection-relevant conditions, and in clinical isolates to...
This $361,237 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a new class of species-specific antimicrobial peptides called PNA-STAMPS to target Streptococcus pneumoniae (Spn), a major human pathogen. The project builds on preliminary data showing that fusing a broad-spectrum antimicrobial peptide (AMP) to an Spn-specific secreted peptide can selectively eliminate...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $184,375 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Florida International University (FIU) to optimize a novel antimicrobial peptide, A4-X7, for pulmonary delivery to combat antimicrobial-resistant respiratory infections. The funded research aims to prepare, characterize, and evaluate the antimicrobial and antibiofilm activities of the A4-X7 formulation for aerosolized...
This $151,040 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the regulatory role of the small regulatory RNA BECO on essential virulence factors in the pathogen Pseudomonas aeruginosa. The research aims to determine how BECO controls the expression of the Type III Secretion System and pyochelin biosynthesis genes, which are critical for P....
This $625,909 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports research and development of a hydrogel platform technology for delivering topical bacteriophage therapy to treat antibiotic-resistant wound infections. The award aims to develop innovative methods for sustained local delivery of bacteriophages - viruses that kill...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $453,629 to Yale University to conduct research on the cell surface of the opportunistic pathogen Pseudomonas aeruginosa. The project, titled "Phage-Seq Phenotyping of the Pseudomonas aeruginosa Surface-ome", aims to develop a high-throughput technology called "Phage-Seq" that can survey bacterial cell surfaces and...